Michael Shi

Dr. Shi oversees HUTCHMED’S discovery and development organization from strategy to execution in China.

Prior to joining HUTCHMED in 2022, Dr. Shi was the Global Head of R&D and Chief Medical Officer at Transcenta where he helped build a strong global research and development organization across China and the U.S. and advanced seven programs into clinical development and multiple preclinical candidate nominations. Before that, Dr. Shi worked at Novartis for over 15 years, where he held various senior leadership positions including Global Program Clinical Head in clinical development. He played key leadership roles in the clinical development of multiple novel oncology/hematology products from clinical proof-of- concept to successful execution of global pivotal trials, product registration and life-cycle management. Dr. Shi is a member of American Society of Clinical Oncology, European Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, Sino-American Pharmaceutical Association and an Executive Committee member of the US-China Anticancer Association (USCACA). Dr. Shi also worked as the Program Director of Genetics Variation at NIH under the direct supervision of NIH director Dr. Francis Collins and was an adjunct assistant professor at the University of Michigan Medical School.

Dr. Shi holds a Ph.D. in Molecular Pharmacology and Toxicology from the University of Southern California, and conducted postdoctoral research at the Harvard Medical School. He received his medical education from Peking Union Medical College.